Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMurnion, Bridin-
dc.contributor.otherCappetta, M.-
dc.description.abstractOBJECTIVES: To describe the baseline characteristics, treatment and retention in patients electively admitted for gamma-hydroxybutyrate (GHB) withdrawal management. METHODS: All patients admitted between July 2010 to June 2016 who used GHB two or more times per week with a minimum duration of 3 months were identified and data extracted by file review. RESULTS: Twelve cases satisfied the inclusion criteria, of whom 50% were female; 75% were using GHB daily, with an average daily amount of 16 ml. Average duration of use was 60 months. All subjects were using amphetamine type stimulants and nicotine. Psychiatric comorbidity and unintentional overdose were common; 50% completed treatment. Medications used included diazepam and neuroleptic. Two patients completed withdrawal with no medications. No subject using greater than 90 ml GHB in the preceding week completed treatment. Pattern of GHB use did not predict medication requirements during withdrawal management. CONCLUSIONS: There were low numbers attending for elective treatment for GHB use. Heavier GHB use predicted poor treatment retention. Polysubstance use and psychiatric co-morbidities need consideration in treatment planning.en
dc.description.sponsorshipDrug & Alcoholen
dc.subjectDrug and Alcoholen
dc.subjectMental Healthen
dc.titleInpatient management of gamma-hydroxybutyrate withdrawalen
dc.typeJournal Articleen
dc.description.affiliatesCentral Coast Local Health Districten
dc.description.affiliatesWyong Hospitalen
dc.identifier.journaltitleAustralasian Psychiatryen
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
Appears in Collections:Mental Health
Show simple item record

Page view(s)

checked on Mar 29, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.